Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
6.39
+0.44 (7.39%)
At close: Apr 17, 2026, 4:00 PM EDT
6.38
-0.01 (-0.16%)
After-hours: Apr 17, 2026, 7:51 PM EDT
Plus Therapeutics Revenue
In the year 2025, Plus Therapeutics had annual revenue of $5.21M, down -10.49%. Plus Therapeutics had revenue of $1.37M in the quarter ending December 31, 2025, a decrease of -3.19%.
Revenue (ttm)
$5.21M
Revenue Growth
-10.49%
P/S Ratio
8.41
Revenue / Employee
$186,179
Employees
28
Market Cap
43.85M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 5.21M | -611.00K | -10.49% |
| Dec 31, 2024 | 5.82M | 911.00K | 18.54% |
| Dec 31, 2023 | 4.91M | 4.69M | 2,093.30% |
| Dec 31, 2022 | 224.00K | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | 303.00K | -6.70M | -95.67% |
| Dec 31, 2019 | 7.00M | 4.02M | 134.60% |
| Dec 31, 2018 | 2.98M | -739.00K | -19.85% |
| Dec 31, 2017 | 3.72M | -3.00M | -44.65% |
| Dec 31, 2016 | 6.72M | -97.00K | -1.42% |
| Dec 31, 2015 | 6.82M | 4.18M | 157.88% |
| Dec 31, 2014 | 2.65M | -2.43M | -47.87% |
| Dec 31, 2013 | 5.07M | -718.00K | -12.40% |
| Dec 31, 2012 | 5.79M | 3.78M | 187.73% |
| Dec 31, 2011 | 2.01M | -360.00K | -15.17% |
| Dec 31, 2010 | 2.37M | -6.52M | -73.32% |
| Dec 31, 2009 | 8.89M | 6.57M | 282.49% |
| Dec 31, 2008 | 2.33M | -2.93M | -55.77% |
| Dec 31, 2007 | 5.26M | -1.22M | -18.82% |
| Dec 31, 2006 | 6.48M | 6.11M | 1,645.55% |
| Dec 31, 2005 | 371.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Celularity | 40.58M |
| Veru Inc. | 16.89M |
| Palatin Technologies | 8.96M |
| CervoMed | 4.01M |
| Lisata Therapeutics | 170.00K |
| Actinium Pharmaceuticals | 90.00K |
PSTV News
- 3 days ago - Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution - GlobeNewsWire
- 9 days ago - Plus Therapeutics Appoints Eric J. Daniels, M.D. - GlobeNewsWire
- 10 days ago - Plus Therapeutics Granted U.S. FDA Orphan Drug Designation to REYOBIQ™ in Pediatric Malignant Gliomas - GlobeNewsWire
- 11 days ago - Plus Therapeutics Receives AMA PLA Code for CNSide® CSF Tumor Cell Enumeration Test, Advancing Reimbursement and U.S. Commercial Adoption - GlobeNewsWire
- 16 days ago - Plus Therapeutics Secures Highmark Coverage for CNSide® CSF Assay, Expanding Reimbursement to ~75 Million Covered Lives - GlobeNewsWire
- 17 days ago - Plus Therapeutics Reports Granting of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 23 days ago - Plus Therapeutics Appoints Diagnostics and Molecular Diagnostics Industry Leader Ron Andrews to its Board of Directors - GlobeNewsWire
- 4 weeks ago - Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40% - GlobeNewsWire